WALTHAM, Mass. — January 5, 2026 — Leads & Copy — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT, according to a statement released today.
The live conference webcast will be available on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
Apellis Pharmaceuticals, Inc. is described as a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. The company states that it ushered in the first new class of complement medicine in 15 years and now has two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. The company believes it has only begun to unlock the potential of targeting C3 across many serious diseases.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
Source: Apellis Pharmaceuticals, Inc.
